Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

Actelion emphasizes commitment to advance research and care in rare diseases (Actelion Ltd)

$
0
0
(Source: Actelion Ltd) 'Patient Voice - Join us in making the voice of rare diseases heard.' This is the theme of Rare Disease Day 2016 - and a cause for Actelion to emphasize its long-term commitment to support the needs of the patient community. ALLSCHWIL, SWITZERLAND - 29 February 2016 - Today, on Rare Disease Day 2016, patients, their families and caregivers, patient organizations, medical professionals, politicians and researchers are coming together to raise awareness for what living with a rare disease means for those affected and for their families. Patients play a crucial role in bringing both research and the standard of care in rare diseases forward, which is recognized in the...

Viewing all articles
Browse latest Browse all 480

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>